Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Burkitt Lymphoma International Prognostic Index

COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement

Simultaneous intraocular and cutaneous extranodal NK/T-cell lymphoma refractory to multiple therapies including pembrolizumab

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

Non-Covalent BTK Inhibitors-The New BTKids on the Block for B-Cell Malignancies

Routine imaging for disease surveillance in follicular lymphoma-To comfort the patients or their doctors?

The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma

Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance